None
DE
Don’t believe the hype: why Trump’s pharma tariffs and looming government shutdown won’t hit investors too hard
['Luke Hopewell']
Switzer Daily
Dr Shane Oliver, AMP’s chief economist, argues the risks to Australian investors are smaller than the headlines suggest.
Last week the Trump administration announced new tariffs aimed at parts of the pharmaceutical industry.
Investors are watching tariff details trickle out while tracking whether Capitol Hill can avoid a lapse in funding.
When it comes to pharma, Dr Oliver says that the full impact is unclear, but it's likely to be negligible.
That's for a few reasons:The impact of the pharmaceutical tariffs on Australia is unclear but is likely to be small.